ALKEM:NSE-Alkem Laboratories Limited (INR)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSE

Last Closing Price

INR 3,121.65

Change

+41.00 (+1.33)%

Market Cap

INR 375.15B

Volume

0.10M

Avg Analyst Target

INR 3,396.67 (+8.81%)

Avg User Target

INR
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

ALKEM Stock Forecast & Price:
Based on the Alkem Laboratories Limited stock forecasts from 2 analysts, the average analyst target price for Alkem Laboratories Limited is INR 3,396.67 over the next 12 months. Alkem Laboratories Limited’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Alkem Laboratories Limited is Slightly Bullish , which is based on 10 positive signals and 6 negative signals. At the last closing, Alkem Laboratories Limited’s stock price was INR 3,121.65. Alkem Laboratories Limited’s stock price has changed by +1.07% over the past week, +0.29% over the past month and -10.98% over the last year.

About Alkem Laboratories Limited (ALKEM:NSE)

Alkem Laboratories Limited, a pharmaceutical company, engages in the development, manufacture, and sale of pharmaceutical and nutraceutical products in India and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, biosimilars, a ...Read More

Company Website : https://www.alkemlabs.com

Address : Devashish Building, Mumbai, India, 400013

Employees : 16,966

Fiscal Year End : March

Currency: INR

Country : India

Technical Indicators

Beta : 0.24

52 Week High : 3,748.90

52 Week Low : 2,824.37

200 Day Moving Average : 3,178.90

50 Day Moving Average : 3,182.51

Shares Held By Insiders : 74.41%

Shares Held by Institutions : 17.38%

Dividend Yield : 1.10%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-11-29 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SUNPHARMA:NSE Sun Pharmaceutical Industries ..

+15.10 (+1.46%)

 INR2,475.75B 60.34 31.77
DIVISLAB:NSE Divi's Laboratories Limited

-2.85 (-0.08%)

 INR897.96B 30.01 21.86
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

+51.35 (+1.17%)

 INR737.83B 23.89 12.86
TORNTPHARM:NSE Torrent Pharmaceuticals Limite..

-1.20 (-0.07%)

 INR549.30B 68.89 27.13
ZYDUSLIFE:NSE Zydus Lifesciences Limited

+5.40 (+1.35%)

 INR405.74B 20.38 12.32
LUPIN:NSE Lupin Limited

+17.80 (+2.43%)

 INR327.29B 476.66 26.10
AUROPHARMA:NSE Aurobindo Pharma Limited

-0.75 (-0.16%)

 INR275.07B 13.03 6.69
LAURUSLABS:NSE Laurus Labs Limited

-41.75 (-9.27%)

 INR244.72B 28.26 16.70
IPCALAB:NSE IPCA Laboratories Limited

-5.80 (-0.66%)

 INR220.48B 35.90 18.33
PEL:NSE Piramal Enterprises Limited

-0.10 (-0.01%)

 INR197.42B 2.60 3.10

ETFs Containing ALKEM

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -13.86% 60% D- 35% F
Dividend Return 0.94% 69% D+ 53% F
Total Return -12.92% 62% D- 36% F
Trailing 12 Months  
Capital Gain -13.13% 52% F 26% F
Dividend Return 0.95% 67% D+ 51% F
Total Return -12.18% 52% F 26% F
Trailing 5 Years  
Capital Gain 57.10% 57% F 68% D+
Dividend Return 4.83% 76% C 65% D
Total Return 61.93% 59% F 68% D+
Average Annual (5 Year Horizon)  
Capital Gain 14.78% 39% F 46% F
Dividend Return 0.79% 76% C 55% F
Total Return 15.57% 39% F 46% F
Risk Return Profile  
Volatility (Standard Deviation) 23.40% 94% A 90% A-
Risk Adjusted Return 66.51% 87% B+ 86% B
Market Capitalization 375.15B 94% A 93% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 34.36 30% F 32% F
Price/Book Ratio 4.01 31% F 29% F
Price / Cash Flow Ratio 33.77 30% F 23% F
EV/EBITDA 21.71 24% F 24% F
Management Effectiveness  
Return on Equity 12.52% 64% D 55% F
Return on Invested Capital 15.64% 75% C 77% C+
Return on Assets 5.52% 58% F 58% F
Debt to Equity Ratio 0.11% 89% B+ 86% B
Technical Ratios  
Dividend Yield 1.10% 69% D+ 59% F
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.24 88% B+ 89% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date
New Post

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment
Stock Target Advisor

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector